DVAX 250117 13.00P (DVAX250117P13000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

DVAX250117P13000

Watchlist

0.67
+0.37+123.33%

15min DelayClose Jan 8 16:00 ET

0.67High0.30Low

Intraday

5D
Daily

News

$960 Mn Vaccine Adjuvants Market by Product, ROA, Disease Type, Vaccine - Global Forecast to 2029 With GSK, Seppic, Croda, SPI Pharma, Phibro Animal Health, Agenus, Dynavax Technologies Dominating
Yahoo FinanceJan 8 09:32 ET
Earnings Call Summary | Dynavax Technologies(DVAX.US) Q3 2024 Earnings Conference
moomoo AIDec 30, 2024 06:25 ET · Conference Call
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
PR NewswireNov 26, 2024 16:05 ET
Do Options Traders Know Something About Dynavax Technologies (DVAX) Stock We Don't?
Zacks Nov 25, 2024 08:10 ET
US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16, 2024 02:13 ET
Dynavax Technologies Down Over 7%, On Track for Largest Percent Decrease Since August 2022 -- Data Talk
Dow JonesNov 15, 2024 13:51 ET

Comments

Jaguar8

Nov 15, 2024 12:54

NEWS

$Dynavax Technologies (DVAX.US)$
Dynavax Technologies Down Over 7%, On Track for Largest Percent Decrease Since August 2022 -- Data Talk
Dow Jones· 2 mins ago2mins
Dynavax Technologies Corporation ( DVAX ) is currently at $12.42, down $0.97 or 7.21%
--Would be lowest close since Nov. 7, 2024, when it closed at $12.02
--On pace for largest percent decrease since Aug. 17, 2022, when it fell 10.39%
--Currently down three of the past four days
--Currently down two consecutive days; down 8.1% ov...

Jaguar8

Nov 7, 2024 15:07

NEWS

$Dynavax Technologies (DVAX.US)$
Dynavax Announces $200 Million Share Repurchase Program
Dynavax (DVAX) reported strong Q3 2024 financial results, with HEPLISAV-Bachieving record quarterly net product revenue of $79.3 million, up 27% year-over-year. The company's total revenues reached $80.6 million, a 16% increase from Q3 2023. HEPLISAV-B's U.S. market share grew to 44%, with particularly strong performance in retail pharmacy (55%) and IDN segments (56%). The company expects the hepatitis B...

Meltyy

May 20, 2024 21:57

🔔 FDA PDUFA Update…

📣 2 PDUFAs left in May!
🗓️ Last week’s PDUFAs:
$Amgen (AMGN.US)$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb (BMY.US)$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies (DVAX.US)$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S (ASND.US)$ : Review extended to 8/14/24 🤔
⇒ YORV...

Trytosaveabit

May 14, 2024 07:34

Grrrr! But it’s already approved in other countries?

$Dynavax Technologies (DVAX.US)$ Reuters· 1 min ago
Dynavax: Crl States Application Did Not Provide Sufficient Data to Support Full Evaluation of Effectiveness or Safety of 4-Dose Regimen of Heplisav-B

Trytosaveabit

May 13, 2024 04:12

Reminder

$Dynavax Technologies (DVAX.US)$ Still on FDA PDUFA calendar today for sBLA 5/13/24